ClinicalTrials.gg
CompletedNCT06097299Updated Aug 18, 2026Results posted

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

A Phase 2 interventional study of mRNA-1345 and Placebo in Respiratory Syncytial Virus, sponsored by ModernaTX, Inc.. Completed at 50 sites in 2 countries. Open to participants aged 2 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
349
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases — none open to participants now, none under way, none of them phase 3. mRNA-1345 respiratory syncytial virus vaccine · Virus Diseases.

Enrollment
9th of 10
349 · median 579
Started
2023
with 3 others
Phase 2
2 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
10 of 10
ModernaTX, Inc.

Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, this one is the 9th largest by enrollment, is one of 4 that started in 2023, is one of 2 in phase 2, and was the 8th registered.

Virus Diseases

656 studies on the registry are indexed under Virus Diseases; 84 are open to participants now.

Browse Virus Diseases studies →

Open to participants now

None of the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases is open now. The open studies under Virus Diseases, anywhere →

About mRNA-1345 respiratory syncytial virus vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 64 Virus Diseases studies recruiting now, 30 (47%) set no upper age limit and 22 (34%) stop at 75 or younger; 28 take children under 18; 27 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases as a file.
02

Study summary

Part A: The purpose is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1345 in children aged 2 to \<5 years (Cohort 1) and in children at high risk of respiratory syncytial virus (RSV) disease 5 to \<18 years of age (Cohort 2) to inform the dose level selection for the next phase of development (Phase 3).

Part B: The purpose is to provide surveillance for RSV disease for the next RSV season (6 months after re-enrollment) and safety follow-up for Cohort 1 participants that were enrolled and dosed in Part A.

03

Conditions studied

  • Respiratory Syncytial Virus

Browse trials for

Keywords

  • Pediatric
  • mRNA-1345
  • RSV vaccine
  • Viral Diseases
  • Messenger RNA
  • Moderna
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Part A Cohort 1:

  • 2 to \<5 years of age at Day 1.
  • Healthy, or with stable chronic conditions increasing the risk of RSV disease, per the clinical judgment of the Investigator.

Cohort 2:

  • 5 to \<18 years of age at Day 1.
  • Participants with stable chronic conditions increasing the risk of RSV disease.
  • Female participants of may be enrolled in the study, if the participant: 1) has a negative urine pregnancy test at Screening and on the day of injection (Day 1); 2) has practiced adequate or has abstained from all activities that could lead to pregnancy for 28 days prior to Day 1; 3) has agreed to continue adequate contraception through 90 days following injection; and 4) is not currently breastfeeding.

Part B: Cohort 1 Re-enrollment

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Enrolled and dosed in Part A of Cohort 1; either reached EoS for Part A or were dosed and subsequently discontinued from study for various reasons. This includes participants who were lost to follow-up, if they can be re-engaged.
  2. Participant's parent(s)/LAR(s) has provided written for participation in this study.

Key Exclusion Criteria (All Cohorts):

  • Acutely ill or febrile (temperature ≥38.0°Celsius [100.4°Fahrenheit]) within 72 hours prior to or at the Screening Visit or Day 1.
  • History of a diagnosis or condition that, in the judgment of the Investigator, may affect study assessment or compromise participant safety.
  • Has received or plans to receive any licensed or authorized vaccine ≤14 days prior to the study vaccine injection (Day 1) or plans to receive a licensed or authorized vaccine within 14 days after the study vaccine injection.
  • Receipt of any prior systemic . Short courses (\<7 days) of oral are allowed if completed at least 3 months prior to enrollment.
  • Receipt of RSV monoclonal antibodies within 6 months prior to enrollment in the study.
  • Participated in an interventional clinical study within 28 days (6 months for a study assessing a product unlicensed/unauthorized in this age group in country of residence at time of enrollment) prior to the day of enrollment or plans to do so while enrolled in this study.

Part B: Cohort 1 Re-enrollment

1. Participant is currently enrolled in another interventional clinical study.

Note: Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
349 participants (actual)

Study arms

  • Experimental
    Part A and Part B: Cohort 1 (2 to <5 Years of Age)

    Part A: Participants 2 to \<5 years of age will receive either a single intramuscular (IM) injection of mRNA-1345 or placebo on Day 1. Part B: Participants will have the option to be re-enrolled into a 6-month safety-follow up period.

    Biological: mRNA-1345 · Biological: Placebo

  • Experimental
    Part A: Cohort 2 (5 to <18 Years of Age)

    Participants 5 to \<18 years of age will receive a single IM injection of mRNA-1345 on Day 1.

    Biological: mRNA-1345

Interventions

  • BiologicalmRNA-1345

    Sterile liquid for injection

  • BiologicalPlacebo

    0.9% sodium chloride (normal saline) injection

06

What researchers measure

Primary outcomes

  1. Part A (Cohorts 1 and 2): Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

    Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Up to 7 days post-injection

  2. Part A (Cohorts 1 and 2): Number of Participants With Unsolicited Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Up to 28 days post-injection

  3. Part A (Cohorts 1 and 2): Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study Discontinuation

    A MAAE was an AE that led to an unscheduled visit to a healthcare practitioner. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Day 1 through end of Part A (Month 6)

  4. Part B (Cohort 1): Number of Participants With RSV-RTD, Respiratory Syncytial Virus- Lower Respiratory Tract Disease (RSV-LRTD), Severe RSV-LRTD, Very Severe RSV-LRTD and RSV Hospitalization Classified by Clinical Assessment Team (CAT)

    RSV-RTD: Runny nose or blocked nose or cough and confirmed RSV infection. RSV-LRTD: Cough or difficulty breathing (Based on Investigator's observation; difficulty breathing included signs of wheezing, stridor, tachypnoea, chest in-drawing or subcostal or intercostal retractions) and peripheral oxygen saturation (SpO2) \<95%, or respiratory rate (RR) increased and confirmed RSV infection. RSV Severe-LRTD: Meeting the definition of RSV-LRTD and SpO2 \<93%, or lower chest wall in-drawing. RSV Very Severe LRTD: Meeting the definition of RSV-LRTD and SpO2 \<90%, or failure to respond/unconscious. RSV Hospitalization: Confirmed RSV and hospitalized for acute medical condition.

    Time frame: Day 1 through end of Part B (Month 6)

Secondary outcomes

  1. Part A (Cohort 1): Geometric Mean Titer (GMT) of Serum RSV Neutralizing Antibody

    Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 international units (IU)/milliliter (mL) for RSV-A and 10 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 112476 IU/mL for RSV-B. 95% confidence interval (CI) for geometric mean (GM) value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.

    Time frame: Day 1, Day 29, and Month 6

  2. Part A (Cohort 1): Geometric Mean Concentration (GMC) of Serum RSV Prefusion F (Pre-F) Binding Antibody

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 arbitrary units (AU)/mL and ULOQ was 580553 AU/mL for RSV Pre-F immunoglobulin G (IgG) antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.

    Time frame: Day 1, Day 29, and Month 6

  3. Part A (Cohort 1): Geometric Mean Fold Rise (GMFR) of Post-baseline/Baseline Neutralizing Antibody Titers

    Antibody values reported as below lower LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL for RSV-A and 10 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 112476 IU/mL for RSV-B. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

    Time frame: Day 29 and Month 6

  4. Part A (Cohort 1): GMFR of Post-baseline/Baseline Binding Antibody Concentrations

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 AU/mL and ULOQ was 580553 AU/mL for RSV Pre-F IgG antibody. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

    Time frame: Day 29 and Month 6

  5. Part A (Cohort 1): Percentage of Participants With Seroresponse in RSV Neutralizing Antibody

    Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.

    Time frame: Baseline to Day 29 and Month 6

  6. Part A (Cohort 1): Percentage of Participants With Seroresponse in RSV Pre-F Binding Antibody

    Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.

    Time frame: Baseline to Day 29 and Month 6

  7. Part A (Cohort 2): GMT of Serum RSV Neutralizing Antibody

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL for RSV-A and 15 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 162163 IU/mL for RSV-B. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.

    Time frame: Day 1 and Day 29

  8. Part A (Cohort 2): GMC of Serum RSV Pre-F Binding Antibody

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 AU/mL and ULOQ was 580553 AU/mL for RSV Pre-F IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.

    Time frame: Day 1 and Day 29

  9. Part A (Cohort 2): GMFR of Post-baseline/Baseline Neutralizing Antibody Titers

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL for RSV-A and 15 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 162163 IU/mL for RSV-B. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

    Time frame: Day 29

  10. Part A (Cohort 2): GMFR of Post-baseline/Baseline Binding Antibody Concentrations

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 AU/mL and ULOQ was 580553 AU/mL for RSV Pre-F IgG antibody. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

    Time frame: Day 29

  11. Part A (Cohort 2): Percentage of Participants With Seroresponse in RSV Neutralizing Antibody

    Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.

    Time frame: Baseline to Day 29

  12. Part A (Cohort 2): Percentage of Participants With Seroresponse in RSV Pre-F Binding Antibody

    Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.

    Time frame: Baseline to Day 29

  13. Part B (Cohort 1): Number of Participants With AESIs and SAEs

    An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Day 1 through Part B EOS (Month 6)

07

Results

Posted Aug 18, 2026

Participant flow

Part A
Participant flow — Part A
MilestonePart A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 2Part A Cohort 2: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4Part B Cohort 1: Received Placebo in Part APart B Cohort 1: Received mRNA-1345 Dose Level 1 in Part APart B Cohort 1: Received mRNA-1345 Dose Level 2 in Part APart B Cohort 1: Received mRNA-1345 Dose Level 3 in Part A
Started414042416261620000
Received study drug injection413941416161620000
Completed353637406059590000
Not completed64512230000
Withdrew: Withdrawal by parent/guardian20002000000
Withdrew: Lost to follow-up43410230000
Withdrew: Protocol violation01000000000
Withdrew: Other than specified00100000000
Part B
Participant flow — Part B
MilestonePart A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 2Part A Cohort 2: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4Part B Cohort 1: Received Placebo in Part APart B Cohort 1: Received mRNA-1345 Dose Level 1 in Part APart B Cohort 1: Received mRNA-1345 Dose Level 2 in Part APart B Cohort 1: Received mRNA-1345 Dose Level 3 in Part A
Started000000019242524
Completed000000019242523
Not completed00000000001
Withdrew: Lost to follow-up00000000001

Outcome measures

PrimaryPart A (Cohorts 1 and 2): Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Up to 7 days post-injection
Reported as:
Count of participants · Participants
Part A (Cohorts 1 and 2): Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
ParticipantsPart A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 2Part A Cohort 2: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4
Part A (Cohorts 1 and 2): Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)18212830454451
PrimaryPart A (Cohorts 1 and 2): Number of Participants With Unsolicited Adverse Events (AEs)

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Up to 28 days post-injection
Reported as:
Count of participants · Participants
Part A (Cohorts 1 and 2): Number of Participants With Unsolicited Adverse Events (AEs)
ParticipantsPart A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 2Part A Cohort 2: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4
Part A (Cohorts 1 and 2): Number of Participants With Unsolicited Adverse Events (AEs)993101156
PrimaryPart A (Cohorts 1 and 2): Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study Discontinuation

A MAAE was an AE that led to an unscheduled visit to a healthcare practitioner. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Day 1 through end of Part A (Month 6)
Reported as:
Count of participants · Participants
Part A (Cohorts 1 and 2): Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study Discontinuation
ParticipantsPart A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 2Part A Cohort 2: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4
MAAEs34591089
AESIs0000000
SAEs0000003
AEs Leading to Study Discontinuation0000000
PrimaryPart B (Cohort 1): Number of Participants With RSV-RTD, Respiratory Syncytial Virus- Lower Respiratory Tract Disease (RSV-LRTD), Severe RSV-LRTD, Very Severe RSV-LRTD and RSV Hospitalization Classified by Clinical Assessment Team (CAT)

RSV-RTD: Runny nose or blocked nose or cough and confirmed RSV infection. RSV-LRTD: Cough or difficulty breathing (Based on Investigator's observation; difficulty breathing included signs of wheezing, stridor, tachypnoea, chest in-drawing or subcostal or intercostal retractions) and peripheral oxygen saturation (SpO2) \<95%, or respiratory rate (RR) increased and confirmed RSV infection. RSV Severe-LRTD: Meeting the definition of RSV-LRTD and SpO2 \<93%, or lower chest wall in-drawing. RSV Very Severe LRTD: Meeting the definition of RSV-LRTD and SpO2 \<90%, or failure to respond/unconscious. RSV Hospitalization: Confirmed RSV and hospitalized for acute medical condition.

Time frame:
Day 1 through end of Part B (Month 6)
Reported as:
Count of participants · Participants
Part B (Cohort 1): Number of Participants With RSV-RTD, Respiratory Syncytial Virus- Lower Respiratory Tract Disease (RSV-LRTD), Severe RSV-LRTD, Very Severe RSV-LRTD and RSV Hospitalization Classified by Clinical Assessment Team (CAT)
ParticipantsPart B Cohort 1: Received Placebo in Part APart B Cohort 1: Received mRNA-1345 Dose Level 1 in Part APart B Cohort 1: Received mRNA-1345 Dose Level 2 in Part APart B Cohort 1: Received mRNA-1345 Dose Level 3 in Part A
RSV-RTD0212
RSV-LRTD0100
RSV Severe LRTD0000
RSV Very-Severe LRTD0000
RSV Hospitalization0000
SecondaryPart A (Cohort 1): Geometric Mean Titer (GMT) of Serum RSV Neutralizing Antibody

Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 international units (IU)/milliliter (mL) for RSV-A and 10 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 112476 IU/mL for RSV-B. 95% confidence interval (CI) for geometric mean (GM) value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.

Time frame:
Day 1, Day 29, and Month 6
Reported as:
Geometric mean · IU/mL
Part A (Cohort 1): Geometric Mean Titer (GMT) of Serum RSV Neutralizing Antibody
IU/mLPart A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3
RSV-A: Day 1742.79 (406.66 to 1356.75)636.62 (335.51 to 1207.99)925.12 (553.23 to 1546.99)1100.06 (642.50 to 1883.48)
RSV-A: Day 29622.62 (365.59 to 1060.36)7548.68 (4715.49 to 12084.11)5454.33 (3321.91 to 8955.59)13963.62 (8733.17 to 22326.68)
RSV-A: Month 6767.32 (521.91 to 1128.13)1978.73 (1207.90 to 3241.47)1975.68 (1339.27 to 2914.51)4129.82 (2471.64 to 6900.43)
RSV-B: Day 1343.19 (193.35 to 609.18)333.68 (187.03 to 595.33)478.93 (293.74 to 780.85)442.16 (266.78 to 732.83)
RSV-B: Day 29310.51 (190.05 to 507.33)2439.14 (1542.12 to 3857.94)2043.38 (1282.91 to 3254.64)3913.01 (2665.38 to 5744.65)
RSV-B: Month 6351.86 (259.00 to 478.01)708.25 (448.51 to 1118.41)746.17 (533.81 to 1043.00)975.64 (654.64 to 1454.04)
SecondaryPart A (Cohort 1): Geometric Mean Concentration (GMC) of Serum RSV Prefusion F (Pre-F) Binding Antibody

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 arbitrary units (AU)/mL and ULOQ was 580553 AU/mL for RSV Pre-F immunoglobulin G (IgG) antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.

Time frame:
Day 1, Day 29, and Month 6
Reported as:
Geometric mean · AU/mL
Part A (Cohort 1): Geometric Mean Concentration (GMC) of Serum RSV Prefusion F (Pre-F) Binding Antibody
AU/mLPart A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3
Day 15666.73 (2740.28 to 11718.45)4824.82 (2238.62 to 10398.78)7759.79 (4418.08 to 13629.08)9200.11 (5456.47 to 15512.24)
Day 295478.04 (2980.57 to 10068.20)60354.43 (43293.29 to 84139.08)52861.15 (36058.06 to 77494.50)93443.87 (69910.72 to 124898.70)
Month 66021.94 (4130.25 to 8780.02)13070.48 (8101.85 to 21086.21)14422.57 (10902.68 to 19078.86)20054.12 (13907.99 to 28916.31)
SecondaryPart A (Cohort 1): Geometric Mean Fold Rise (GMFR) of Post-baseline/Baseline Neutralizing Antibody Titers

Antibody values reported as below lower LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL for RSV-A and 10 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 112476 IU/mL for RSV-B. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

Time frame:
Day 29 and Month 6
Reported as:
Geometric mean · ratio
Part A (Cohort 1): Geometric Mean Fold Rise (GMFR) of Post-baseline/Baseline Neutralizing Antibody Titers
ratioPart A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3
RSV-A: Day 290.84 (0.68 to 1.04)11.86 (7.23 to 19.43)5.90 (3.55 to 9.79)12.69 (7.74 to 20.82)
RSV-A: Month 60.90 (0.57 to 1.40)3.66 (2.41 to 5.56)1.70 (0.95 to 3.05)3.78 (2.33 to 6.13)
RSV-B: Day 290.81 (0.66 to 0.99)7.31 (4.82 to 11.08)4.27 (2.74 to 6.64)8.85 (5.59 to 14.02)
RSV-B: Month 60.99 (0.65 to 1.53)2.46 (1.72 to 3.52)1.23 (0.74 to 2.04)2.12 (1.30 to 3.45)
SecondaryPart A (Cohort 1): GMFR of Post-baseline/Baseline Binding Antibody Concentrations

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 AU/mL and ULOQ was 580553 AU/mL for RSV Pre-F IgG antibody. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

Time frame:
Day 29 and Month 6
Reported as:
Geometric mean · ratio
Part A (Cohort 1): GMFR of Post-baseline/Baseline Binding Antibody Concentrations
ratioPart A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3
Day 290.94 (0.76 to 1.17)13.43 (6.78 to 26.58)6.63 (4.18 to 10.52)10.16 (6.53 to 15.79)
Month 60.81 (0.48 to 1.37)2.86 (1.68 to 4.87)1.28 (0.81 to 2.05)2.16 (1.41 to 3.33)
SecondaryPart A (Cohort 1): Percentage of Participants With Seroresponse in RSV Neutralizing Antibody

Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.

Time frame:
Baseline to Day 29 and Month 6
Reported as:
Number · percentage of participants
Part A (Cohort 1): Percentage of Participants With Seroresponse in RSV Neutralizing Antibody
percentage of participantsPart A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3
RSV-A: Day 292.6 (0.1 to 13.5)78.9 (62.7 to 90.4)46.3 (30.7 to 62.6)79.5 (63.5 to 90.7)
RSV-A: Month 69.1 (1.9 to 24.3)50.0 (32.4 to 67.6)28.6 (14.6 to 46.3)52.6 (35.8 to 69.0)
RSV-B: Day 290 (0.0 to 9.5)63.2 (46.0 to 78.2)48.8 (32.9 to 64.9)71.8 (55.1 to 85.0)
RSV-B: Month 69.1 (1.9 to 24.3)26.5 (12.9 to 44.4)22.9 (10.4 to 40.1)39.5 (24.0 to 56.6)
SecondaryPart A (Cohort 1): Percentage of Participants With Seroresponse in RSV Pre-F Binding Antibody

Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.

Time frame:
Baseline to Day 29 and Month 6
Reported as:
Number · percentage of participants
Part A (Cohort 1): Percentage of Participants With Seroresponse in RSV Pre-F Binding Antibody
percentage of participantsPart A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3
Day 292.6 (0.1 to 13.8)75.0 (57.8 to 87.9)53.8 (37.2 to 69.9)74.4 (57.9 to 87.0)
Month 66.3 (0.8 to 20.8)21.9 (9.3 to 40.0)17.1 (6.6 to 33.6)36.8 (21.8 to 54.0)
SecondaryPart A (Cohort 2): GMT of Serum RSV Neutralizing Antibody

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL for RSV-A and 15 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 162163 IU/mL for RSV-B. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.

Time frame:
Day 1 and Day 29
Reported as:
Geometric mean · IU/mL
Part A (Cohort 2): GMT of Serum RSV Neutralizing Antibody
IU/mLPart A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4
RSV-A: Day 11260.25 ± 943.551027.77 ± 749.051230.06 ± 946.64
RSV-A: Day 2910168.70 ± 7560.529011.13 ± 6239.7019541.50 ± 15311.61
RSV-B: Day 1669.76 ± 506.07617.58 ± 449.58581.70 ± 463.11
RSV-B: Day 293105.78 ± 2498.973523.27 ± 2598.784782.51 ± 4006.02
SecondaryPart A (Cohort 2): GMC of Serum RSV Pre-F Binding Antibody

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 AU/mL and ULOQ was 580553 AU/mL for RSV Pre-F IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.

Time frame:
Day 1 and Day 29
Reported as:
Geometric mean · AU/mL
Part A (Cohort 2): GMC of Serum RSV Pre-F Binding Antibody
AU/mLPart A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4
Day 111060.58 ± 8799.389556.54 ± 7002.3511882.31 ± 10029.95
Day 2967394.60 ± 54544.9869494.70 ± 55349.62109004.49 ± 94312.25
SecondaryPart A (Cohort 2): GMFR of Post-baseline/Baseline Neutralizing Antibody Titers

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL for RSV-A and 15 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 162163 IU/mL for RSV-B. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

Time frame:
Day 29
Reported as:
Geometric mean · ratio
Part A (Cohort 2): GMFR of Post-baseline/Baseline Neutralizing Antibody Titers
ratioPart A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4
RSV-A8.07 ± 6.178.77 ± 6.2615.89 ± 11.92
RSV-B4.64 ± 3.615.71 ± 4.218.22 ± 6.53
SecondaryPart A (Cohort 2): GMFR of Post-baseline/Baseline Binding Antibody Concentrations

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 AU/mL and ULOQ was 580553 AU/mL for RSV Pre-F IgG antibody. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

Time frame:
Day 29
Reported as:
Geometric mean · ratio
Part A (Cohort 2): GMFR of Post-baseline/Baseline Binding Antibody Concentrations
ratioPart A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4
Part A (Cohort 2): GMFR of Post-baseline/Baseline Binding Antibody Concentrations6.09 ± 4.777.27 ± 5.439.17 ± 7.65
SecondaryPart A (Cohort 2): Percentage of Participants With Seroresponse in RSV Neutralizing Antibody

Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.

Time frame:
Baseline to Day 29
Reported as:
Number · percentage of participants
Part A (Cohort 2): Percentage of Participants With Seroresponse in RSV Neutralizing Antibody
percentage of participantsPart A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4
RSV-A76.3 ± 63.475.9 ± 62.886.7 ± 75.4
RSV-B54.2 ± 40.860.3 ± 46.671.7 ± 58.6
SecondaryPart A (Cohort 2): Percentage of Participants With Seroresponse in RSV Pre-F Binding Antibody

Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.

Time frame:
Baseline to Day 29
Reported as:
Number · percentage of participants
Part A (Cohort 2): Percentage of Participants With Seroresponse in RSV Pre-F Binding Antibody
percentage of participantsPart A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4
Part A (Cohort 2): Percentage of Participants With Seroresponse in RSV Pre-F Binding Antibody69.5 ± 56.174.1 ± 61.088.3 ± 77.4
SecondaryPart B (Cohort 1): Number of Participants With AESIs and SAEs

An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Day 1 through Part B EOS (Month 6)
Reported as:
Count of participants · Participants
Part B (Cohort 1): Number of Participants With AESIs and SAEs
ParticipantsPart B Cohort 1: Received Placebo in Part APart B Cohort 1: Received mRNA-1345 Dose Level 1 in Part APart B Cohort 1: Received mRNA-1345 Dose Level 2 in Part APart B Cohort 1: Received mRNA-1345 Dose Level 3 in Part A
AESIs0100
SAEs0010

Adverse events

Collected over All-cause mortality, SAEs, AESIs, MAAEs, and AEs leading to study discontinuation: up to Month 6 (Parts A & B). Other (non-serious) AEs: up to 28 days after study injection, unless they met criteria for AESIs, MAAEs, or AEs led to study discontinuation.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Cohort 1: Placebo0/41 (0%)0/41 (0%)1/41 (2.4%)
Part A Cohort 1: mRNA-1345 Dose Level 10/39 (0%)0/39 (0%)3/39 (7.7%)
Part A Cohort 1: mRNA-1345 Dose Level 20/41 (0%)0/41 (0%)1/41 (2.4%)
Part A Cohort 1: mRNA-1345 Dose Level 30/41 (0%)0/41 (0%)7/41 (17.1%)
Part A Cohort 2: mRNA-1345 Dose Level 20/61 (0%)0/61 (0%)5/61 (8.2%)
Part A Cohort 2: mRNA-1345 Dose Level 30/61 (0%)0/61 (0%)0/61 (0%)
Part A Cohort 2: mRNA-1345 Dose Level 40/62 (0%)3/62 (4.8%)0/62 (0%)
Part B Cohort 1: Received Placebo in Part A0/19 (0%)0/19 (0%)0/19 (0%)
Part B Cohort 1: Received mRNA-1345 Dose Level 1 in Part A0/24 (0%)0/24 (0%)0/24 (0%)
Part B Cohort 1: Received mRNA-1345 Dose Level 2 in Part A0/25 (0%)1/25 (4%)0/25 (0%)
Part B Cohort 1: Received mRNA-1345 Dose Level 3 in Part A0/24 (0%)0/24 (0%)0/24 (0%)
Most frequent serious events
Most frequent serious events
EventPart A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 2Part A Cohort 2: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4Part B Cohort 1: Received Placebo in Part APart B Cohort 1: Received mRNA-1345 Dose Level 1 in Part APart B Cohort 1: Received mRNA-1345 Dose Level 2 in Part APart B Cohort 1: Received mRNA-1345 Dose Level 3 in Part A
InfluenzaInfections and infestations0/410/390/410/410/610/610/620/190/241/250/24
AsthmaRespiratory, thoracic and mediastinal disorders0/410/390/410/410/610/612/620/190/240/250/24
Post procedural haemorrhageInjury, poisoning and procedural complications0/410/390/410/410/610/611/620/190/240/250/24
Most frequent other events
Most frequent other events
EventPart A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 2Part A Cohort 2: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4Part B Cohort 1: Received Placebo in Part APart B Cohort 1: Received mRNA-1345 Dose Level 1 in Part APart B Cohort 1: Received mRNA-1345 Dose Level 2 in Part APart B Cohort 1: Received mRNA-1345 Dose Level 3 in Part A
Upper respiratory tract infectionInfections and infestations1/411/390/414/413/610/610/620/190/240/250/24
Pharyngitis streptococcalInfections and infestations0/410/391/413/411/610/610/620/190/240/250/24
Gastroenteritis viralInfections and infestations0/412/390/410/411/610/610/620/190/240/250/24

Baseline characteristics

The Randomization Set included all participants who were randomized in the study, regardless of the participant's treatment status in the study. For Part B, all Cohort 1 participants who were enrolled and dosed in Part A, were offered to re-enroll into the safety follow-up study.

Age, Customized
Age, Customized(Participants)Part A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 2Part A Cohort 2: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4Total
In utero00000000
Preterm newborn infants (gestational age < 37 wks)00000000
Newborns (0-27 days)00000000
Infants and toddlers (28 days-23 months)00000000
Children (2-11 years)41404241303031255
Adolescents (12-17 years)000032313194
Adults (18-64 years)00000000
From 65-84 years00000000
85 years and over00000000
Sex: Female, Male
Sex: Female, Male(Participants)Part A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 2Part A Cohort 2: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4Total
Female20221726332335176
Male21182515293827173
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 2Part A Cohort 2: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4Total
Hispanic or Latino14111419141715104
Not Hispanic or Latino27292822484447245
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A Cohort 1: PlaceboPart A Cohort 1: mRNA-1345 Dose Level 1Part A Cohort 1: mRNA-1345 Dose Level 2Part A Cohort 1: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 2Part A Cohort 2: mRNA-1345 Dose Level 3Part A Cohort 2: mRNA-1345 Dose Level 4Total
American Indian or Alaska Native00000000
Asian11121017
Native Hawaiian or Other Pacific Islander00000000
Black or African American141168203128118
White25263230382731209
More than one race123133215
Unknown or Not Reported00000000
08

Study locations

50 sites
  • Velocity Clinical Research, Phoenix
    Phoenix, Arizona 85006, United States
  • Headlands Research - Scottsdale
    Scottsdale, Arizona 85260, United States
  • Velocity Clinical Research - Banning
    Banning, California 92220, United States
  • ASCADA Research, LLC - Family Medicine
    Fullerton, California 92835, United States
  • Ark Clinical Research
    Long Beach, California 90815, United States
  • Peninsula Research Associates (PRA)
    Rolling Hills Estates, California 90274, United States
  • D&amp;H Doral Research Center, LLC
    Doral, Florida 33122, United States
  • Kissimmee Clinical Research
    Kissimmee, Florida 34741, United States
  • Accel Clinical
    Largo, Florida 33777, United States
  • Med-Care Research
    Miami, Florida 33125, United States
  • Accel Research Sites - Nona Pediatric Center
    Orlando, Florida 32829, United States
  • SEC Clinical Research
    Pensacola, Florida 32501, United States
  • D&H Tamarac Research Center
    Tamarac, Florida 33321, United States
  • Javara, Inc.
    Fayetteville, Georgia 30214, United States
  • Velocity Clinical Research-Primary Pediatrics, Macon
    Macon, Georgia 31210, United States
  • CenExel iResearch, LLC
    Savannah, Georgia 31405, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Velocity Clinical Research - Boise
    Meridian, Idaho 83642, United States
  • Alliance for Multispeciality Research, LLC
    El Dorado, Kansas 67042, United States
  • Velocity Clinical Research-Kansas City
    Overland Park, Kansas 66210, United States
  • Velocity Clinical Research - Lafayette
    Lafayette, Louisiana 70508, United States
  • Velocity Clinical Research Metairie
    Metairie, Louisiana 70006, United States
  • Great Lakes Research Institute
    Southfield, Michigan 48075, United States
  • Pediatric &amp; Adolescent Center
    Southgate, Michigan 48195-1896, United States
  • Clinical Research Institute
    Minneapolis, Minnesota 55402, United States
  • Velocity Clinical Research, Gulfport
    Gulfport, Mississippi 39503, United States
  • Velocity Clinical Research- Albuquerque
    Albuquerque, New Mexico 87107, United States
  • Velocity Clinical Research-Binghamton
    Binghamton, New York 13905, United States
  • University of Rochester Medical Center (URMC) - Golisano Children's Hospital (GCH)
    Rochester, New York 14620, United States
  • Senders Pediatrics
    South Euclid, Ohio 44121, United States
  • The Children's Hospital of Philadelphia - Pediatrics
    Philadelphia, Pennsylvania 19104-4318, United States
  • DM Clinical Research - Philadelphia
    Philadelphia, Pennsylvania 19107, United States
  • Velocity Clinical Research - Providence
    Providence, Rhode Island 02886, United States
  • Coastal Pediatric Research
    Charleston, South Carolina 29414, United States
  • Tribe Clinical Research
    Simpsonville, South Carolina 29680, United States
  • Elligo Clinical Research Center
    Austin, Texas 78704, United States
  • REX Clinical Trials, LLC
    Beaumont, Texas 77701, United States
  • Javara Inc (Conroe)
    Conroe, Texas 77384, United States
  • West Houston Clinical Research Service
    Houston, Texas 77055, United States
  • DM Clinical Research - CyFair
    Houston, Texas 77065, United States
  • Village Pediatrics
    Plano, Texas 75024, United States
  • Javara Inc/Texas Health Care, PLLC d/b/a/ Privia Medical Group-North Texas
    Stephenville, Texas 76401, United States
  • Victoria Clinical Research Group
    Victoria, Texas 77901, United States
  • Velocity Clinical Research - Salt Lake City
    West Jordan, Utah 84088, United States
  • PI-Coor Clinical Research, LLC
    Annandale, Virginia 22003, United States
  • Clinical Research Partners
    Richmond, Virginia 23226, United States
  • National Clinical Research, Inc.
    Richmond, Virginia 23294, United States
  • CEVAXIN Chorrera
    La Chorrera, 07066, Panama
  • CEVAXIN Avenida Mexico
    Panama City, 07093, Panama
  • CEVAXIN 24 de Diciembre
    Panama City, 07114, Panama
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Jun 2025, 20 months.

Results were first posted in Aug 2026, 1 year 1 month after primary completion.

Of 34 industry-sponsored phase 2 interventional studies under Virus Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 20 months is above that.

Counting every sponsor, half of 58 studies reached it within 16 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2023
First posted
Oct 24, 2023
StartActual
Oct 24, 2023
Primary completionActual
Jun 27, 2025
CompletionActual
Jun 27, 2025
Results first posted
Aug 18, 2026
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06097299
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Oct 24, 2023
Start date
Oct 24, 2023
Primary completion
Jun 27, 2025
Completion
Jun 27, 2025
Results posted
Aug 18, 2026
Last update
Aug 18, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1345 respiratory syncytial virus vaccine

Start the discussion